Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
September 29, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
Panelists:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
Related Insights
June 17, 2025
Health Care Law Today
Oregon’s New Corporate Practice of Medicine Restrictions: Five Takeaways for Digital Health and Telemedicine Companies
On June 9, 2025, Oregon’s governor signed SB 951 into law, making Oregon one of the most restrictive states in the country with respect…
June 17, 2025
Foley Viewpoints
Federal Court Enforces Forum Selection Clause in Dealer Dispute with Equipment Manufacturer
A federal district court recently enforced a forum selection clause in National Equipment Dealers, LLC v. IROCK Crushers LLC,…
June 17, 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About … Mitigating Risks Posed by the New Trump Administration Focus on Drug Cartels and TCOs
The Trump Administration’s crackdown on cartels and transnational criminal organizations operating abroad and in the United States is a significant Department of Justice priority.